Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Merimepodib · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| Merimepodib | DRUG | - |
| PEG-Interferon-alpha 2a (Pegasys®) | DRUG | - |
| Ribavirin (Copegus®) | DRUG | - |
Inclusion Criteria: The following is a summary of the inclusion and exclusion criteria for the Merimepodib Triple Combination (METRO) trial. There are also additional criteria, which will be reviewed with you by the staff at the clinical study site, to make sure you are eligible for the study. Some...
Top 1 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir |
Merimepodib is an investigational small molecule developed for the treatment of chronic hepatitis C, a viral infection of the liver. It was studied as part of a triple combination regimen in adults 18 years and older. It is not an approved therapy and remains in clinical development.
Merimepodib targets IMPDH1, inosine monophosphate dehydrogenase 1, and acts as an inhibitor of that enzyme. Inhibiting IMPDH1 interferes with guanine nucleotide synthesis, which is a pathway the hepatitis C virus relies on for replication. This mechanism is distinct from direct-acting antiviral approaches.
Merimepodib was developed by Vertex Pharmaceuticals Incorporated, which trades on the Nasdaq under the ticker VRTX. Vertex sponsored the clinical program evaluating the compound in chronic hepatitis C. The drug is an investigational small molecule and is not a marketed product.
Merimepodib reached Phase 2 clinical development for chronic hepatitis C. It is an investigational agent and is not FDA approved. The Phase 2 program has concluded, with one completed trial and no active trials currently listed for the compound.
Merimepodib was evaluated in the Phase 2 trial NCT00088504, titled Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C. The trial enrolled 315 participants across sites in the United States, used a randomized, double-blind design, and has been completed.
No. Merimepodib was studied in chronic hepatitis C without biomarker-based patient selection. The Phase 2 trial NCT00088504 enrolled adults 18 years and older of all sexes, excluded healthy volunteers, and did not restrict enrollment to a biomarker-defined subgroup of patients.